Guardant Health (NASDAQ:GH) Now Covered by Analysts at Barclays

Stock analysts at Barclays initiated coverage on shares of Guardant Health (NASDAQ:GH) in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $60.00 price target on the stock. Barclays‘s price target suggests a potential upside of 27.09% from the company’s current price.

Other analysts also recently issued research reports about the stock. Sanford C. Bernstein reduced their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. The Goldman Sachs Group lifted their price target on shares of Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Guggenheim reissued a “buy” rating on shares of Guardant Health in a research report on Wednesday. JPMorgan Chase & Co. raised their target price on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Leerink Partners dropped their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Sixteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health presently has an average rating of “Buy” and an average price target of $41.81.

Guardant Health Stock Down 2.9 %

GH stock opened at $47.21 on Thursday. The firm has a market cap of $5.83 billion, a price-to-earnings ratio of -11.13 and a beta of 1.28. The company’s fifty day simple moving average is $35.26 and its 200 day simple moving average is $29.53. Guardant Health has a 12-month low of $15.81 and a 12-month high of $49.86.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The business had revenue of $191.48 million during the quarter, compared to analyst estimates of $170.49 million. During the same period in the prior year, the firm earned ($0.73) earnings per share. The firm’s revenue for the quarter was up 33.9% compared to the same quarter last year. Research analysts expect that Guardant Health will post -3.44 earnings per share for the current year.

Insider Buying and Selling at Guardant Health

In related news, Director Meghan V. Joyce sold 2,896 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the transaction, the director now directly owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Musa Tariq sold 2,320 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the transaction, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. The trade was a 46.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,548 shares of company stock worth $179,782. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Guardant Health

Hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. raised its stake in shares of Guardant Health by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,198 shares of the company’s stock valued at $800,000 after buying an additional 2,537 shares during the period. R Squared Ltd bought a new stake in Guardant Health in the 4th quarter valued at about $26,000. KBC Group NV lifted its holdings in Guardant Health by 63.6% during the fourth quarter. KBC Group NV now owns 5,658 shares of the company’s stock valued at $173,000 after purchasing an additional 2,200 shares during the last quarter. Wealthcare Advisory Partners LLC purchased a new stake in Guardant Health during the fourth quarter valued at about $252,000. Finally, Fiduciary Alliance LLC boosted its position in Guardant Health by 7.6% during the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock worth $363,000 after purchasing an additional 836 shares during the period. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.